This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.

LNP3794 in patients with Advanced Solid Tumours having Mutations

  • Research type

    Research Study

  • Full title

    A Phase 1 Study of LNP3794 in Patients with Advanced Solid Tumors having RAS/BRAF Mutations

  • IRAS ID

    157025

  • Contact name

    Udai Banerji

  • Contact email

    Udai.banerji@icr.ac.uk

  • Sponsor organisation

    Lupin Limited

  • Eudract number

    2014-001536-10

  • Research summary

    LNP3794 is an experimental drug that is being developed for the treatment of various types of cancer such as skin cancer, pancreatic cancer, non-small cell lung carcinoma, colorectal cancer, or thyroid cancer. It acts by blocking an exnzyme (a protein) called MEK, important for the growth of tumour cells. The enzyme MEK has been shown to be activated in solid tumours with mutations in the BRAF and RAS genes, which are involved in cancer cell growth.

    This is a Phase I study. The purpose of this study is to determine the highest safe dose (maximum tolerated dose) of LNP3794 when administered orally to adult patients with advanced solid tumour that have progressed despite standard therapy, or for which no standard therapy exists.

    A total of approximately 17 patients will participate in this study at multiple locations internationally. The study will be run at approximately 2 centres in the UK and is sponsored by Lupin Ltd.

  • REC name

    London - Surrey Borders Research Ethics Committee

  • REC reference

    14/LO/1171

  • Date of REC Opinion

    7 Aug 2014

  • REC opinion

    Further Information Favourable Opinion